THE CHOICE OF THE METHOD OF ENDOSCOPIC STENTING IN PATIENTS WITH UNRESECTABLE ADENOCARCINOMA OF THE PANCREATIC HEAD
https://doi.org/10.21294/1814-4861-2020-19-3-116-121
Abstract
The purpose of the study was to comparatively assess the endoscopic plastic or nitinol stenting in patients with unresectable adenocarcinoma of the pancreatic head, who subsequently received systemic chemotherapy.
Material and Methods. Between 2014 and 2018, 64 patients underwent retrograde stenting followed by chemotherapy. All patients were divided into 2 groups. Group I consisted of 21 patients, who underwent nitinol stent implantation. Group II comprised 43 patients, who underwent plastic stent implantation.
Results. The technical success was 91.3 % in group I and 93.5 % in group II (р=0.324); clinical success was 95.2 % in group I and 90.6 % in group II (р=0.218). Complications according to the Clavien–Dindo classification in group I patients: Grade II in 2 (9.5 %), Grade III in 1 (4.5 %), and Grade IV 2 in (9.5 %). In group II patients, these complications were as follows: Grade II in 4 (9.3 %), Grade III in 4 (9.3 %), and Grade IV in 1 (2.3 %). The median duration of chemotherapy was 127.3 days. Stent dysfunction was observed in 5 (23.8 %) patients of group I and in 24 (55.8 %) patients of group II (р=0.026). The median time of stent patency was 108 ± 5.2 days in group I and 64 ± 4.3 days in group II (р=0.034). In group I patients, the median survival time was 100 days in 5 patients, 120 days in 9 patients, and 150 days in 5 patients. Two patients are alive. In group II patients, the median survival time was 100 days in 10, 120 days in 16, and 150 days in 13. Five patients are alive.
Conclusion. Based on the results obtained, it is advisable to recommend the use of nitinol stents for resolving obstructive jaundice in patients with unresectable ductal adenocarcinoma of the pancreatic head, who are scheduled to undergo chemotherapy.
About the Authors
A. V. Shabunin
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian Federation;
S.P. Botkin Municipal Clinical Hospital
Russian Federation
Russian Federation
MD, DSc, Corresponding Member of the Russian Academy of Sciences, Head of the Department of Surgery, 2/1, Barricadnaya Street, 125993, Moscow;
Chief Physician, 2, 2nd Botkinsky Prospect, 125284, Moscow
M. M. Tavobilov
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian Federation;
S.P. Botkin Municipal Clinical Hospital
Russian Federation
Russian Federation
MD, DSc, Associate Professor of the Department of Surgery, 2/1, Barricadnaya Street, 125993, Moscow;
Head of the Department of Hepatopancreatobiliary Surgery, 2, 2nd Botkinsky Prospect, 125284, Moscow
S. S. Lebedev
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian Federation;
S.P. Botkin Municipal Clinical Hospital
Russian Federation
Russian Federation
MD, PhD, Associate Professor of the Department of Surgery, 2/1, Barricadnaya Street, 125993, Moscow;;
2, 2nd Botkinsky Prospect, 125284, Moscow
I. Yu. Korzheva
S.P. Botkin Municipal Clinical Hospital
Russian Federation
Russian Federation
MD, DSc, Head of the Department of Endoscopy,
2, 2nd Botkinsky Prospect, 125284, Moscow
A. A. Karpov
S.P. Botkin Municipal Clinical Hospital
Russian Federation
Russian Federation
MD, DSc, Head of the Department of Endoscopy,
2, 2nd Botkinsky Prospect, 125284, Moscowv
A. V. Lantsynova
S.P. Botkin Municipal Clinical Hospital
Russian Federation
Russian Federation
MD, Surgeon of the Department of Hepatopancreatobiliary Surgery,
2, 2nd Botkinsky Prospect, 125284, Moscowv
References
1. Rawla P., Sunkara T., Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol. 2019; 10(1): 10–27. doi: 10.14740/wjon1166.
2. McGuigan A., Kelly P., Turkington R.C., Jones C., Coleman H.G., McCain R.S. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018; 24(43): 4846–61. doi: 10.3748/wjg.v24.i43.4846.
3. Lee P.J., Podugu A., Wu D., Lee A.C., Stevens T., Windsor J.A. Preoperative biliary drainage in resectable pancreatic cancer: a systematic review and network meta-analysis. HPB (Oxford). 2018 Jun; 20(6): 477–486. doi: 10.1016/j.hpb.2017.12.007.
4. Boulay B.R., Parepally M. Managing malignant biliary obstruction in pancreas cancer: choosing the appropriate strategy. World J Gastroenterol. 2014; 20(28): 9345–9353. doi:10.3748/wjg.v20.i28.9345.
5. Matsumoto K., Kato H., Horiguchi S., Tsutsumi K., Saragai Y., Takada S., Mizukawa S., Muro S., Uchida D., Tomoda T., Okada H. Efficacy and safety of chemotherapy after endoscopic double stenting for malignant duodenal and biliary obstructions in patients with advanced pancreatic cancer: a single-institution retrospective analysis. BMC Gastroenterol. 2018 Oct 26; 18(1): 157. doi: 10.1186/s12876-018-0886-8.
6. Walter D., van Boeckel P.G., Groenen M.J., Weusten B.L., Witteman B.J., Tan G., Brink M.A., Nicolai J., Tan A.C., Alderliesten J., Venneman N.G., Laleman W., Jansen J.M., Bodelier A., Wolters F.L., van der Waaij L.A., Breumelhof R., Peters F.T., Scheffer R.C., Leenders M., Hirdes M.M., Steyerberg E.W., Vleggaar F.P., Siersema P.D. Cost efficacy of metal stents for palliation of extrahepatic bile duct obstruction in a randomized controlled trial. Gastroenterology. 2015; 149: 130–138. doi: 10.1053/j.gastro.2015.03.012.
Review
For citations:
Shabunin A.V., Tavobilov M.M., Lebedev S.S., Korzheva I.Yu., Karpov A.A., Lantsynova A.V. THE CHOICE OF THE METHOD OF ENDOSCOPIC STENTING IN PATIENTS WITH UNRESECTABLE ADENOCARCINOMA OF THE PANCREATIC HEAD. Siberian journal of oncology. 2020;19(3):116-121. (In Russ.) https://doi.org/10.21294/1814-4861-2020-19-3-116-121
Views:
761
Email this article 
